Skip to content

Study · Non-randomized trial · n = 2 · 2016

3 results

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Grüters A, Krude H

The New England journal of medicine1 Jul 2016Cited by 339 (Europe PMC)

PMID27468060 (opens in a new tab)DOI10.1056/nejmoa1512693 (opens in a new tab)PepBankPUB-27468060
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In two patients with proopiomelanocortin deficiency, setmelanotide produced a sustained reduction in hunger.

    In plain wordsIn two patients with proopiomelanocortin deficiency, hunger decreased sustainably with setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHunger
    Study

    n = 2

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patients had a sustainable reduction in hunger and substantial weight loss (51.0 kg after 42 weeks in Patient 1 and 20.5 kg after 12 weeks in Patient 2).
    1 context sentence
    Summary · context
    In this investigator-initiated, open-label study, two patients with proopiomelanocortin deficiency were treated with setmelanotide, a new melanocortin-4 receptor agonist.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Patient 1 with proopiomelanocortin deficiency, weight decreased by 51.0 kg after 42 weeks with setmelanotide.

    In plain wordsIn Patient 1 with proopiomelanocortin deficiency, weight decreased by 51.0 kg after 42 weeks with setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight loss in Patient 1
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    51 kg
    Patient 1 after 42 weeks

    Source sentences

    Summary
    The patients had a sustainable reduction in hunger and substantial weight loss (51.0 kg after 42 weeks in Patient 1 and 20.5 kg after 12 weeks in Patient 2).
    1 context sentence
    Summary · context
    In this investigator-initiated, open-label study, two patients with proopiomelanocortin deficiency were treated with setmelanotide, a new melanocortin-4 receptor agonist.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Patient 2 with proopiomelanocortin deficiency, weight decreased by 20.5 kg after 12 weeks with setmelanotide.

    In plain wordsIn Patient 2 with proopiomelanocortin deficiency, weight decreased by 20.5 kg after 12 weeks with setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight loss in Patient 2
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    20.5 kg
    Patient 2 after 12 weeks

    Source sentences

    Summary
    The patients had a sustainable reduction in hunger and substantial weight loss (51.0 kg after 42 weeks in Patient 1 and 20.5 kg after 12 weeks in Patient 2).
    1 context sentence
    Summary · context
    In this investigator-initiated, open-label study, two patients with proopiomelanocortin deficiency were treated with setmelanotide, a new melanocortin-4 receptor agonist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.